EGFR-Targeted Therapy for Squamous NCSLC
In the second‑line patients, distinctions of the SATURN trial, where only 11% of the placebo patients got erlotinib, here, I think it was 77%.
The claim highlights the comparative efficacy of erlotinib in a maintenance setting versus a control, indicating significant improvement in patient outcomes in the second‑line skin‑cancer population.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation
- Breathtaking Breakthrough: Lung-on-a-Chip Defends Itself | News Center
- A Life-Saving Breakthrough: Scientists Uncover Japanese Fruit Juice That May Help Prevent Lung Cancer
- Breakthrough cancer therapy stops tumor growth without harming healthy cells
- People with lung cancer have more microplastics in their lungs